NASA's Jet Propulsion Laboratory (JPL) has developed ventilators to reduce global shortages caused by COVID-19.
The ventilators passed the "high-fidelity human simulation lab" tests at New York's Icahn School of Medicine at Mount Sinai. The U.S. Food and Drug Administration (FDA) has already approved the device for Emergency Use Authorization.
Known as VITAL (Ventilator Intervention Technology Accessible Locally), the device was designed in 37 days for low-cost mass production with almost one-seventh of typical ventilator parts. With a 3 – 4 month lifespan, the machines cannot replace existing ventilators but can ease shortages in temporary hospitals.6
The FDA's authorization was "a key milestone in a process that exemplifies the best of what government can do in a time of crisis," NASA Administrator Jim Bridenstine said in a statement. "This ventilator is one of countless examples of how taxpayer investments in space exploration – the skills, expertise, and knowledge collected over decades of pushing boundaries and achieving firsts for humanity – translate into advancements that improve life on Earth."
At the time of this writing, the California Institute of Technology, which is in partnership with NASA's JPL, had planned to approve free use and was searching for manufacturers in the medical sector to rapidly distribute VITAL to hospitals.
This article was originally written in Japanese. All images and content are directly from the Japanese version at the time of publication.